01 Ai & Big Data Integration in Drug RepurposingThe integration of AI and big data analytics in drug repurposing is boosting drug discovery, improving accuracy, and reducing costs. AI-driven platforms analyze vast biomedical datasets, including genomics, proteomics, and clinical trial records, to identify new therapeutic applications for existing drugs.For instance, in August 2024, Rejuvenate Biomed partnered with SAS to develop an AI-driven drug repurposing discovery tool on SAS Viya, a cloud-native platform. This tool will help researchers uncover hidden biological patterns, accelerating drug-disease insights and innovation.Such growing adoption of AI and big data is transforming drug repurposing, enhancing efficiency, and boosting the global market.
02 Rising Focus on Rare & Orphan DiseasesThe increasing focus on rare and orphan diseases is propelling the global market, as traditional drug development for these conditions is often costly and time-consuming. Regulatory incentives such as orphan drug designations, tax credits, and market exclusivity further boost pharmaceutical companies to explore repurposed drugs, accelerating treatment availability for rare diseases.For instance, in August 2024, Harvard Medical School researchers introduced TxGNN, the first AI model specifically developed to identify drug candidates for rare diseases. TxGNN, a graph foundation model, leverages medical knowledge graphs and neural networks to predict drug indications and contraindications across 17,080 diseases, including rare conditions.The combination of AI-driven innovations and a rising focus on rare diseases is expanding treatment options and significantly boosting market growth.
01 Growing Prevalence of Chronic & Neurodegenerative DiseasesThe rising prevalence of chronic and neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and multiple sclerosis, is a major driver of the market for drug repurposing. With limited treatment options and high failure rates in novel drug development, repurposing existing drugs offers a faster, cost-effective alternative.The combination of rising patient populations and advancements in drug repurposing technologies is accelerating the development of effective, accessible, and rapidly deployable treatment solutions, fueling market growth.
02 Regulatory Support & Fast-Track ApprovalsRegulatory agencies worldwide are increasingly supporting drug repurposing through fast-track approvals, orphan drug designations, and priority review pathways. These initiatives help accelerate the commercialization of repurposed drugs, reducing development time and costs. The FDA’s 505(b)(2) pathway and EMA’s adaptive licensing enable quicker approvals by leveraging existing safety and efficacy data.Such fast-track approvals highlight the crucial role of regulatory support in driving the global market, ensuring faster access to life-saving treatments for patients.
01 Regulatory Challenges for Higher ConcentrationsThe market faces challenges from the availability of generics and low-cost alternatives, which can limit the commercial viability of repurposed drugs. As many repurposed drugs are based on off-patent compounds, generic manufacturers can introduce cheaper alternatives, reducing market exclusivity and profitability for pharmaceutical companies.The lack of strong intellectual property (IP) protection for repurposed drugs makes it difficult for companies to secure long-term revenue streams, discouraging investment in repurposing efforts. Moreover, pricing pressures from healthcare systems and reimbursement challenges further impact the market adoption of repurposed drugs, limiting their commercial success.
01 Rising Government & Non-Profit Funding InitiativesIncreasing government grants, research funding, and non-profit collaborations are unlocking new opportunities in the global drug repurposing market. Public health agencies and non-profit organizations are actively supporting drug repurposing efforts to expedite treatment availability, particularly for rare diseases and unmet medical needs.Such funding initiatives are expected to drive innovation, improve drug accessibility, and expand market opportunities, reinforcing drug repurposing as a cost-effective and time-efficient alternative to traditional drug development.
September 2025 Insilico Medicine expanded its AI-driven drug discovery capabilities by advancing platform technologies that support target identification, molecule discovery, and potential drug repurposing applications.
July 2025 Healx expanded its AI-based drug discovery and repurposing platform by advancing rare disease research programs, using machine learning approaches to identify potential treatment opportunities from existing drug candidates.
June 2025 Recursion expanded its AI-powered drug discovery platform by strengthening technology collaborations and research initiatives focused on identifying new indications for existing and novel molecules through large-scale biological data analysis.
May 2025 BenevolentAI expanded its artificial intelligence-driven drug discovery platform by advancing AI-enabled drug repurposing capabilities, supporting identification of new therapeutic applications for existing compounds across multiple disease areas.